KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.96

Assessing time to symptomatic progression, a patient-relevant efficacy endpoint, in the MARIPOSA study in non-small cell lung cancer.

Danny Nguyen, Se-Hoon Lee, Shun Lu, Nicolas Girard, Chien-Chung Lin, Enriqueta Felip, Andres Aguilar, Chaiyut Charoentum, Felipe Melo Cruz, Hiroaki Akamatsu, Ruben Kowalyszyn, Cagatay Arslan, Martin D Forster, Damien Urban, Daniel Misch, Lizbett Vanessa García Montes, Shirish M Gadgeel, Marcia Cruz-Correa, Scott Owen, Wolfgang Schuette, Jan Sermon, Ronja Kerßenboom, Markus Frosien, Janka Meißner, Priya Ord, Mariah Ennis, Elizabeth Fennema, Seema Sethi, Joshua M Bauml, Mahesh Daksh, Byoung Chul Cho

Eur J Cancer 245 116938

PMID42492306
PMCID-
DOI10.1016/j.ejca.2026.116938
发表日期2026-07-23
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
摘要

摘要

INTRODUCTION: In the phase 3 randomized MARIPOSA study, amivantamab and lazertinib combination therapy demonstrated improved progression-free survival (PFS) and overall survival (OS) versus osimertinib in participants with previously untreated, epidermal growth factor receptor-mutated advanced non-small cell lung cancer. Time to symptomatic progression (TTSP) was introduced to assess clinical worsening and complement endpoints that investigate radiographic disease progression and patient-reported outcomes. TTSP provides an easily interpretable measure of disease-specific symptom worsening to further support patient experience. METHODS: In MARIPOSA, TTSP was quantitatively assessed as a secondary efficacy endpoint and defined as the time from randomization until participants experience disease-specific symptom worsening requiring a clinical intervention or treatment change, or death. To evaluate the impact of amivantamab and lazertinib on TTSP considering its established OS benefit against osimertinib, an exploratory analysis censoring death events was performed. RESULTS: At the final protocol-specified OS analysis (median follow up: 37.8 months), median TTSP was 43.6 months with amivantamab and lazertinib versus 29.3 months with osimertinib (hazard ratio [HR]: 0.69; 95% confidence interval [CI]: 0.57-0.83; p < 0.0001). Amivantamab and lazertinib reduced deaths following a TTSP event compared to osimertinib. A strong correlation between TTSP and PFS or OS was observed. CONCLUSIONS: Amivantamab and lazertinib significantly delayed TTSP versus osimertinib. TTSP offers a clinician-validated measurement of disease-specific symptom worsening, capturing symptoms perceived by patients that prompt clinical action. TTSP is highly correlated with PFS and OS, providing complementary insights alongside traditional endpoints. TTSP enhances understanding of treatment benefit and supports informed clinical decision-making by integrating patient experience.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。